Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Lacombe

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|May 3, 2025
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of CancerFábio Cardoso Borges, Winette T A van der Graaf, Robbe Saesen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialMartin J van den Bent, Antoine F Carpentier, Alba A Brandes, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2017
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paperMatti Aapro, Alain Astier, Riccardo Audisio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast CancerMarleen Kok, Robbert-Jan Gielen, Sylvia Adams, et al.
Nature Medicine|January 6, 2026
Reduce bureaucracy in clinical trials nowMartin Dreyling, Sara Badreh Wirström, Wolfgang E Berdel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, et al.
The Lancet. Healthy Longevity|November 17, 2023
Inclusion of functional measures and frailty in the development and evaluation of medicines for older adultsMichael Denkinger, Wilma Knol, Antonio Cherubini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 3, 2022
QUARTET: A SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancerSarah M Kelly, Rachel Effeney, Mark N Gaze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial TumorsAndrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|May 3, 2025
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of CancerFábio Cardoso Borges, Winette T A van der Graaf, Robbe Saesen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialMartin J van den Bent, Antoine F Carpentier, Alba A Brandes, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2017
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paperMatti Aapro, Alain Astier, Riccardo Audisio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast CancerMarleen Kok, Robbert-Jan Gielen, Sylvia Adams, et al.
Nature Medicine|January 6, 2026
Reduce bureaucracy in clinical trials nowMartin Dreyling, Sara Badreh Wirström, Wolfgang E Berdel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, et al.
The Lancet. Healthy Longevity|November 17, 2023
Inclusion of functional measures and frailty in the development and evaluation of medicines for older adultsMichael Denkinger, Wilma Knol, Antonio Cherubini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 3, 2022
QUARTET: A SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancerSarah M Kelly, Rachel Effeney, Mark N Gaze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial TumorsAndrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Pageof 12